# | Company | Description | HQ Location | Team Presence | Founded | Employees | Total Funding Raised | Funding Status |
|---|---|---|---|---|---|---|---|---|
Total Companies59 | ||||||||
1 | Over the past decade we have transformed into a focused leader in health technology.
At Philips, our purpose is to improve people’s health and well-being through meaningful innovation. We aim to improve 2.5 billion lives per year by 2030, including 400 million in underserved communities.
We see healthcare as a connected whole. Helping people to live healthily and prevent disease. Giving clinicians the tools they need to make a precision diagnosis and deliver personalized treatment. Aiding the patient's recovery at home in the community. All supported by a seamless flow of data.
As a technology company, we – and our brand licensees – innovate for people with one consistent belief: there’s always a way to make life better.
Visit our website: http://www.philips.com/
Follow our social media house rules https://www.philips.com/a-w/about-philips/social-media.html | Netherlands | United States (27.5%), India (17.1%), Netherlands (14.5%) | 1891 | 10000+ | $518,660,000 | Venture - Series Unknown, $518.66M, June 26, 2024 | |
2 | Provider and developer of diabetes management platforms and solutions intended to help people with diabetes. The company offers blood glucose monitoring devices, insulin delivery systems, an integrated sugar monitoring application, and an intelligent diabetes care platform. Also, it provides online coaching to improve self-care for better outcomes and lower costs. | Switzerland | — | 1896 | 1001-5000 | — | — | |
3 | Every day millions of people feel the impact of our intelligent devices, advanced analytics and artificial intelligence. As a leading global medical technology and digital solutions innovator, GE HealthCare enables clinicians to make faster, more informed decisions through intelligent devices, data analytics, applications and services, supported by its Edison intelligence platform.
With over 100 years of healthcare industry experience and around 50,000 employees globally, the company operates at the center of an ecosystem working toward precision health, digitizing healthcare, helping drive productivity and improve outcomes for patients, providers, health systems and researchers around the world.
We embrace a culture of respect, transparency, integrity and diversity and we work to create a world where healthcare has no limits. | United States | United States (38.2%), India (13.3%), France (5.6%) | 1892 | 10000+ | $5,550,660,836 | Venture - Series Unknown, January 4, 2023 | |
4 | At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.
Learn more at https://www.jnj.com.
Community Guidelines: http://www.jnj.com/social-media-community-guidelines | United States | United States (39.3%), Brazil (5.8%), India (5.7%) | 1886 | 10000+ | $1,492,520 | Venture - Series Unknown, September 24, 1944 | |
5 | Ovia Health by Labcorp offers a leading digital platform dedicated to supporting the full spectrum of women’s health, from preconception through menopause. Our clinical programs provide women with personalized guidance, data-driven insights, and access to over 50 clinical programs and personalized health pathways designed to help improve health outcomes, reduce unnecessary healthcare costs, and support retention and return to work.
Since 2012, we’ve supported millions of women and families on their health and parenthood journeys, offering the only women’s and family health solution proven to effectively identify and intervene with high-risk conditions. Our mission is simple: to help women feel informed, connected, and cared for at every age and stage of life. | United States | United States (98.5%), Canada (1.5%) | 2011 | 51-200 | $23,304,887 | Venture - Series Unknown, August 12, 2021 | |
6 | The AI-powered hormone health app for women.
Now available for iOS: http://apple.co/45WoArI | United States | — | 2022 | 1-10 | — | — | |
7 | Developer of an AI-based healthcare platform designed to tackle the costly, chronic condition burden faced by women starting with endocrine disorders. The company's platform reduces the risk of chronic conditions in women, and more, thereby empowering physicians to deliver tailored, and effective care. | United States | — | 2022 | — | — | — | |
8 | Grace Health, owned by Penda Health, is pioneering the health sector with the first-ever digital women’s health clinic designed for the next billion women online. By leveraging high tech mobile technology in a light weight way, we deliver instant access to women’s health services and information at scale. Grace is solving the current problem of accessibility and discretion by delivering a scalable platform to the 1.9 billion women in emerging markets who own their own phone but lack access to women’s health services and information.
Our automated health assistant, Grace, lets women track and understand their reproductive health, get notifications and reminders ahead of time and dive into our extensive educational content. Grace Health also lets women book discounted appointments with an extensive network of local health facilities. | Sweden | United States (66.7%), Spain (33.3%) | 2018 | 11-50 | $5,100,000 | Venture - Series Unknown, November 1, 2023 | |
9 | illumigyn is a global revolution in women's healthcare - My body, my scan.
illumigyn makes the visit to a gynecologist more effective, pleasant and safe. We bring 21st-Century technology to the world of gynecology. | Israel | Israel (80%), United States (20%) | 2012 | 11-50 | $33,000,000 | Venture - Series Unknown, $33.00M, November 3, 2021 | |
10 | Maven Clinic is the world's largest virtual clinic for women and families on a mission to make healthcare work for all of us. Through Maven Enterprise, the company partners with more than 2,300 employers and health plans to provide end-to-end women's and family health programs spanning fertility and family building, maternity and newborn care, parenting and pediatrics, and menopause and midlife — improving clinical outcomes, reducing healthcare costs, and expanding equitable access to high-quality care at scale. Through its consumer platform, Maven provides direct access to virtual care across 30+ specialties, as well as dedicated hormone and GLP-1 care programs purpose-built for women.
Founded in 2014 by CEO Kate Ryder, Maven Clinic has raised more than $425 million from leading healthcare and technology investors including General Catalyst, Sequoia, Dragoneer Investment Group, Oak HC/FT, StepStone Group, Icon Ventures, and Lux Capital. Recognized for innovation and industry leadership, Maven has been named to the TIME100 Most Influential Companies, CNBC Disruptor 50, Fast Company's Most Innovative Companies, and FORTUNE Best Places to Work. Learn more at mavenclinic.com | United States | United States (90.5%), United Kingdom (2%), Canada (1.6%) | 2014 | 201-500 | $412,300,000 | Venture - Series Unknown, $125.00M, October 8, 2024 | |
11 | Elektra Health is reimagining women's health -- in perimenopause and beyond -- with a virtual care model for women navigating the midlife decades.
Our approach combines evidence-based clinical care, coaching support, and peer community to deliver whole-person, patient-centered care. We build trust and engagement through every step of this often-overlooked life stage.
Elektra partners with over 25 health plans and health systems—including Medicaid, Medicare, and commercial payers—to expand access, close care gaps, and improve outcomes.
Led by seasoned healthcare operators and championed by renowned physicians, Elektra has been featured in The New York Times, Fast Company, Forbes, Vogue, TechCrunch, WSJ, and Fortune, and honored by Maria Shriver, Katie Couric, and Dr. Jill Biden at the White House. | United States | United States (100%) | 2019 | 1-10 | $12,198,257 | Venture - Series Unknown, $4.65M, February 7, 2025 | |
12 | Vira Health is a portfolio of employer-focused products built to support people across key life stages - from fertility and pregnancy through parenting and perimenopause.
We deliver care through three trusted brands: Vira Health (employee benefit platform), Stella (specialist online menopause clinic), and The Lowdown (largest women’s health community in the world).
We're trusted by global employers including GSK, Telus Health, Aon, Optum, and Discovery, with members in over 100+ countries. Fast to launch, tailored to your needs, and delivering great member experience at scale. | United Kingdom | United Kingdom (63.9%), United States (19.4%), Iran (2.8%) | 2020 | 11-50 | $14,064,205 | Venture - Series Unknown, $11.97M, March 14, 2022 | |
13 | At Flo Health, our purpose is to build a better future for female health. We are the world’s leading period and ovulation tracker, empowering over 400 million women globally to take control of their health. With 77 million monthly active users, including 25% of US women, Flo has become a trusted partner in women's health. As the first European femtech unicorn, following a $230M Series C in July 2024, we're proud to lead the way in innovation and investment in women's health.
With over 100+ medical experts, Flo is committed to supporting women at every stage of their health journey, from menstruation to conception, pregnancy, and menopause. We provide curated cycle and ovulation tracking, tailored health insights, daily bite-sized visual content, and a private community for users to share their questions and concerns.
Flo addresses critical challenges in women’s health by:
*Expanding access: Through partnerships like UNFPA, Flo provides free Premium access to up to 1 billion women in 66 countries, with 17 million subscriptions donated, helping bridge healthcare disparities.
*Improving health literacy: By delivering accurate, accessible information and daily insights, Flo empowers millions to better understand their health and make informed decisions.
*Advancing women's health research: Collaborating with leading institutions, Flo contributes to evidence-based women’s health research.
In a world where women's health data is increasingly vulnerable, Flo is dedicated to providing a safe and secure platform. Recognized for its commitment to privacy, Flo's Anonymous Mode feature was named one of TIME's Best Inventions of 2023 and a finalist for Fast Company's 2023 World Changing Ideas Awards. Anonymous Mode allows users to access Flo's health features without associating personal information with their health data, setting a new industry standard for reproductive health data privacy. | United Kingdom | United Kingdom (40.8%), Lithuania (35.9%), Poland (6.3%) | 2015 | 501-1000 | $275,500,000 | Venture - Series Unknown, October 12, 2026 | |
14 | Allara is the first collaborative care platform for women with chronic health conditions creating a new way for women to get the care they need.
Get started today www.allarahealth.com | United States | United States (97.8%), Philippines (1.7%), Brazil (0.6%) | 2020 | 11-50 | $68,500,000 | Venture - Series Unknown, $30.00M, October 13, 2026 | |
15 | Hertility is a data-driven women’s health platform combining advanced diagnostics, proprietary AI-powered clinical decision support, and end-to-end care to enable earlier, faster, and more accurate detection and treatment across the female lifespan.
Hertility has built the world’s largest multimodal dataset in women’s health, powering a clinical-grade AI diagnostic that screens for 25 health states (including 18 conditions) with 98–99% precision, validated across 29 research studies. This is paired with a Software as a Medical Device (SaMD) and integrated patient management system that automates clinical workflows, including AI-assisted ultrasound interpretation and automated reporting, enabling clinicians to scale care delivery efficiently.
In the next 6 months, alongside the NVIDIA inception programme, they will scale globally and initiate the first foundational AI model for women’s health.
We’re calling this the Reproductive Revolution! | United Kingdom | United Kingdom (90.2%), Australia (1.6%), Ireland (1.6%) | 2019 | 11-50 | $15,182,240 | Venture - Series Unknown, $3.92M, October 9, 2024 | |
16 | The EMMA Consortium, comprised of Nura Health, Lasa Health, and Dama Health, was created to accelerate innovation in endometriosis care. Our vision is to revolutionize early, non-invasive diagnosis of endometriosis paired with effective personalized treatment, in order to help solve a debilitating chronic condition impacting more than 1 in 10 women worldwide.
The EMMA Consortium, supported by funding from the Advanced Research Projects Agency for Health (ARPA-H), are pioneering a novel solution for endometriosis, combining genetic, clinical, and biomarker data to eliminate delayed diagnosis and ineffective treatments. Our comprehensive precision medicine platform, the Endometriosis Multimodal Management Application (EMMA), accelerates the early diagnosis and personalized treatment of endometriosis by:
* Developing a non-invasive diagnostic test for endometriosis
* Identifying phenotype-driven genetic & biological markers that influence treatment response
* Improve treatment matching for existing and new therapies
We have launched an IRB-approved clinical study, the EMMA study, for women aged 18-50 years old with or without a clinical diagnosis of endometriosis. To learn more and check your eligibility, please visit https://www.lasahealth.com/emma
The EMMA Consortium
----------------------
Nura Health
www.getnura.com
----------------------
Lasa Health
www.lasahealth.com
----------------------
Dama Health
www.damahealth.com
---------------------- | United States | — | 2024 | 11-50 | $3,000,000 | Venture - Series Unknown, $3.00M, October 23, 2024 | |
17 | NxGen MDx LLC is a leading women’s health company delivering precise genetic screening through best-in-class science, unrivaled accuracy, and personal genetic counseling.
Unlike other laboratories, NxGen’s technology examines the entire gene rather than parts of the gene, giving families a comprehensive assessment of their true risk. With over 99% accuracy, doctors rely on our best-in-class genetic screens as trusted tools for early family planning.
For more information, visit www.nxgenmdx.com. | United States | United States (94.9%), South Africa (2.6%), Australia (2.6%) | 2012 | 51-200 | $1,460,000 | Venture - Series Unknown, $1.46M, April 7, 2020 | |
18 | — | Germany | — | — | 1-10 | — | — | |
19 | Chorus Health is a human-centered healthcare technology company that provides a digital health platform for perimenopausal women and beyond. The company was founded in 2019 and is based in San Francisco, California. | United States | — | 2019 | 1-10 | $120,000 | Venture - Series Unknown, $120.00K, September 16, 2019 | |
20 | Spółka Centra Genetyki Medycznej GENESIS to jedna z wiodących firm genetycznych, specjalizująca się w poradnictwie i badaniach genetycznych. Funkcjonuje na rynku usług medycznych nieprzerwanie od ponad 20 lat.
Centra Genetyki Medycznej GENESIS zatrudnia wykwalifikowany zespół lekarzy specjalistów i diagnostów laboratoryjnych, którzy każdego dnia udzielają Pacjentom kompleksowo świadczeń w zakresie poradnictwa i badań genetycznych.
Zespół CGM GENESIS specjalizuje się m.in. w:
• Diagnostyce rzadkich chorób genetycznych
• Diagnostyce poronień, wad wrodzonych, zaburzeń wzrastania, opóźnień rozwoju, niepełnosprawności intelektualnej oraz autyzmu
• Diagnostyce par z niepowodzeniami rozrodu
• Diagnostyce nowotworowej
Lekarze Specjaliści udzielają pacjentom kompleksowej pomocy w obszarze diagnostyki genetycznej. Wizyta w poradni to przede wszystkim fachowa konsultacja lekarska, wsparcie merytoryczne po otrzymaniu wyniku oraz zalecenia profilaktyczne.
Zespół lekarzy i diagnostów zdobywał i nadal poszerza swoje doświadczenie zawodowe w znanych ośrodkach akademickich i instytutach naukowych w kraju oraz w znakomitych ośrodkach badawczych i klinicznych za granicą.
Podmiot leczniczy współpracuje z licznymi ośrodkami naukowymi krajowymi i zagranicznymi oraz stowarzyszeniami pacjentów i ich rodzin.
Jako wiodąca firma genetyczna, pomogła już tysiącom pacjentów z Polski i zagranicy. Udało się to, dzięki posiadaniu zespołu wykwalifikowanych lekarzy specjalistów genetyki klinicznej i diagnostów laboratoryjnych ze specjalizacją z laboratoryjnej genetyki medycznej.
Chcąc dotrzeć do jak najszerszej grupy pacjentów Spółka nieustannie poszerza swoją ofertę badań.
Wykorzystując zaawansowane technologie i najnowsze odkrycia medycyny, każdego dnia dąży do rozwoju stawiając sobie jako wartość nadrzędną ochronę zdrowia i życia naszych pacjentów. | Poland | Poland (100%) | 1998 | 51-200 | — | — | |
21 | Digital Care for Women over 40. Coming Soon. | United States | Greece (50%), Belgium (50%) | 2018 | 1-10 | — | Venture - Series Unknown, March 26, 2024 | |
22 | Operator of a social network intended to connect clinics and share data to improve women's health using artificial intelligence. The company's technology uses global cloud infrastructure, decentralized federated learning, and automated data cleaning to analyze globally distributed medical data in a private and protected manner, to create online AI applications, enabling healthcare industry to collectively, collaboratively, and safely contribute to medical data. | United States | — | 2016 | 11-50 | $6,478,272 | Venture - Series Unknown, $2.24M, August 1, 2021 | |
23 | FemiSpace is the only digital platform that integrates research and personalized AI-based services for women’s general and reproductive health. | United States | Bangladesh (50%), United States (50%) | 2026 | 11-50 | — | — | |
24 | Plackal develops S/W for mobile devices. Our expertise covers all major platforms - Android, iOS, Windows & Web Apps | India | — | 2012 | 1-10 | — | — | |
25 | daisies is the first subscription based health program in LATAM designed specifically for women, we use an AI powered pre consultation protocol that improves diagnosis and optimizes time and costs. | Mexico | Mexico (94.1%), Spain (5.9%) | 2021 | 11-50 | $50,000 | Venture - Series Unknown, $50.00K, October 31, 2022 | |